Mobile-health Network Solutions Reports 77 Percent Revenue Increase for Fiscal Year 2024

Rhea-AI Summary

Mobile-health Network Solutions (MNDR) reported significant financial results for fiscal year 2024. Revenue increased 77% to $14.0 million, up from $7.9 million in FY2023, driven by telemedicine services growth. Gross profit rose 132% to $2.5 million, with margin improving to 18.2%. However, the company's net loss widened to $15.6 million ($0.56 per share) from $3.2 million in FY2023, primarily due to increased operating expenses, including a $9.1 million non-cash share-based compensation. Cash position improved to $6.7 million, despite increased cash burn in operations of $6.4 million.

Positive

• Revenue growth of 77% year-over-year to $14.0 million
• Gross profit increased 132% to $2.5 million
• Gross margin improved from 13.9% to 18.2%
• 70% increase in telemedicine cases
• Cash position strengthened to $6.7 million from $2.2 million

Negative

• Net loss widened to $15.6 million from $3.2 million
• Operating expenses increased by $13.9 million (316%)
• Cash burn in operations increased to $6.4 million from $2.2 million
• Share dilution with outstanding shares increasing to 27.8M from 25.5M

Insights

Financial Analyst

The 77% revenue growth to $14.0 million demonstrates strong market traction, but significant concerns emerge from the financials. The 316% surge in operating expenses led to a widening net loss of $15.6 million, five times higher than FY23's loss of $3.2 million. While $9.1 million of this was non-cash share compensation, the core operational expenses still increased substantially.

The gross margin improvement to 18.2% from 13.9% shows some operational leverage, but it remains thin for a technology platform. The $6.4 million cash burn from operations is concerning given only $6.7 million cash on hand, suggesting potential need for additional funding within 12 months despite management's optimism about reduced expenses in FY25.

Healthcare Market Analyst

The 70% increase in telemedicine cases indicates strong product-market fit in the APAC healthcare sector. The company's strategy of offering comprehensive specialist access 24/7 addresses a critical gap in Southeast Asian healthcare delivery. However, the rising operational costs, particularly in IT infrastructure and business development, suggest aggressive expansion that needs to be carefully balanced against cash burn.

While the growth trajectory is promising, the company must demonstrate ability to scale efficiently. The current gross margin, though improving, is still below industry standards for mature telehealth platforms, which typically operate at 30-40% margins.

SINGAPORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced that for the fiscal year 2024 ended June 30, 2024, the Company had revenue of $14.0 million, a $6.1 million, or 77 percent, improvement on revenue of $7.9 million for fiscal 2023. This improvement was due to increased revenue of $6.0 million contributed by the Company’s telemedicine and other services segment, and $0.1 million by MNDR’s sale of medicine and medical devices segment.

Cost of revenue increased by $4.7 million, or 69 percent, in fiscal 2024, mainly due to a 70 percent increase in the number of telemedicine cases compared to fiscal 2023.

Cash used in operating activities in fiscal 2024 was $6.4 million as compared to $2.2 million in fiscal 2023.

The Company’s gross profit increased by $1.4 million, or 132 percent, to $2.5 million during FY 2024, mainly due to the 77 percent year-over-year increase in revenue and an increase in gross profit margin to 18.2 percent during FY24 from 13.9 percent during FY23.

Due however to a $13.9 million, or 316 percent, increase in total operating expenses in fiscal 2024 compared to the previous fiscal year, the company incurred a net loss of $15.6 million, or $(.56) per share, for fiscal 2024, as compared to a net loss of $3.2 million, or $(.13) per share, for fiscal 2023.

The largest contributor to the $13.9 million increase in fiscal 2024 total operating expenses was a $9.1 million non-cash, share-based compensation expense during that year, compared to zero for fiscal 2023. This expense consisted primarily of share-based payments to employees pursuant to the Company’s established Employee Incentive Plan and to non-employees in consideration for IPO-related and business development services rendered to the Company.

Fiscal 2024’s increase in total operating expenses also comprised a $3.0 million increase in selling, general, and administrative expenses mainly due to increases in IPO-related professional fees, IT-related cloud server maintenance expenses, traveling, business development, and insurance expenses; an increase of $1.6 million in salaries and benefits for staff who contributed significantly to the Company’s successful IPO and fiscal 2024 increase in revenue; and a $0.1 million increase in depreciation and amortization expenses arising from a new office lease entered during FY 2024.

Cash and cash equivalents at June 30, 2024, and June 30, 2023, was $6.7 million and $2.2 million, respectively. The total weighted number of shares outstanding was 27,808,375 at June 30, 2024, and 25,482,000 at June 30, 2023

“We are proud to have achieved substantial improvements in both our total revenue and total number of telemedicine cases during fiscal 2024,” said co-CEO Dr. Siaw Tung Yeng, PBM, Senior Consultant Family Physician. “Looking forward to fiscal 2025, we are confident that the non-cash, share-based compensation to non-employees and IPO-related portions of our total operating expenses will decline sharply from fiscal 2024 levels, thus significantly boosting our bottom line.”

Co-CEO Dr. Rachel Teoh Pui Pui, PBM, Family Physician, added, “Our unique identity as an affordable, quality, 24/7 provider of telehealth services offering nearly all types of medical specialists available on a near-instantaneous basis is establishing an ever-wider footprint in Singapore and across southeast Asia. We believe this growth will continue to accelerate in the years ahead.”

To view the F-1 filing detailing complete details of the Company’s fiscal 2024 financial performance, please go to https://investors.manadr.com/sec-filings or consult the SEC website at https://www.sec.gov/edgar/search/#/ciks=0001976695&entityName=Mobile-health%2520Network%2520Solutions%2520(MNDR)%2520(CIK%25200001976695)

About Mobile-health Network Solutions

Ranked #41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies, we are the first telehealth provider from the Asia-Pacific region to be listed in the US. Through our MaNaDr platform, we offer personalized and reliable medical attention to users worldwide. Our platform allows our community of healthcare providers to have a broader reach to users through virtual clinics without any start-up costs and the ability to connect to a global network of peer-to-peer support groups and partners. Our range of seamless and hassle-free telehealth solutions includes teleconsultation services, prescription fulfillment and other personalized services such as weight management programs and gender-specific care. For more information, please visit https://investors.manadr.com/.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to execute our strategies, manage growth and maintain our corporate culture; the Company's future business development, financial conditions and results of operations; expectations regarding demand for and market acceptance of our products and services; changes in technology; economic conditions; the growth of the telehealth solutions industry in Singapore and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Singapore and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Mobile-health Network Solutions specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

For media inquiries, please contact:
Mobile-health Network Solutions Investor Relations Contact:
2 Venture Drive, #07-06/07 Vision Exchange
Singapore 608526
(+65) 6222 5223
Email: investors@manadr.com

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5^th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com

Statement of Operations
	Year Ended June 30,
	2024		2023		2022		2024 to 2023		2023 to 2022
	USD		USD		USD		% Change		% Change
Revenue	13,968,535		7,874,886		6,988,849		77.4		12.7
Cost of revenue	(11,430,162	)	(6,779,892	)	(5,053,743	)	68.6		34.2
Gross profit	2,538,373		1,094,994		1,935,106		131.8		(43.4	)
Operating expenses:
Salaries and benefits	4,045,692		2,389,892		1,038,877		69.3		130.0
Depreciation and amortization	149,078		94,816		87,094		57.2		8.9
Selling, general and administrative	4,927,584		1,898,986		615,473		159.5		208.5
Share-based compensation	9,119,764		-		-		100.0		-
Total operating expenses	18,242,118		4,383,694		1,741,444		316.1		151.7
Other income:
Government incentives	-		27,892		2,357		(100.0	)	1,083.4
Other income, net	81,759		47,448		62,453		72.3		(24.0	)
Total other income, net	81,759		75,340		64,810		8.5		16.2
(Loss) income before income tax expense	(15,621,986	)	(3,213,360	)	258,472		386.2		(1,343.2	)
Income tax credit (expense)	19,194		-		(165,775	)	100.0		(100.0	)
Net (loss) income	(15,602,792	)	(3,213,360	)	92,697		385.6		(3,566.5	)
Foreign currency translation, net of income tax	139,230		396,262		(114,433	)	(64.9	)	(446.3	)
Comprehensive loss	(15,463,562	)	(2,817,098	)	(21,736	)	448.9		12,860.5

Balance Sheet
	As of June, 30
	2024		2023
	US$		US$
ASSETS
Current assets
Cash and cash equivalents	6,707,695		2,225,806
Accounts receivable, net	111,066		74,315
Inventories, net	163,993		146,381
Other current assets	222,737		164,410
Amount due from related parties	83,563		106,897
Total current assets	7,289,054		2,717,809
Non-current assets
Plant and equipment, net	216,047		178,799
Intangible assets, net	18,952		70,783
Operating leases right-of-use assets	370,607		393,198
Other assets	55,955		81,950
Total non-current assets	661,561		724,730
TOTAL ASSETS	7,950,615		3,442,539
LIABILITIES
Current liabilities
Accounts payable	1,671,201		1,358,816
Accruals and other payables	1,078,094		826,167
Amount due to officers	133,544		133,586
Amount due to related parties	35,367		26,915
Operating lease liabilities, current	240,090		154,604
Total current liabilities	3,158,296		2,500,088
Non-current liabilities
Amount due to officers	516,946		994,708
Other liabilities	-		73,763
Operating lease liabilities	135,920		241,179
Total non-current liabilities	652,866		1,309,650
TOTAL LIABILITIES	3,811,162		3,809,738
SHAREHOLDERS’ EQUITY (DEFICIT)
Ordinary shares, Class A, $0.000004 par value, 6,250,000,000 shares authorized, 22,413,462 and 13,403,750 shares issued and outstanding as of June 30, 2024 and 2023, respectively	89		53
Ordinary shares, Class B, $0.000004 par value, 6,250,000,000 shares authorized, 12,078,250 shares issued and outstanding as of June 30, 2024 and 2023, respectively	49		49
Additional paid-in capital	28,466,888		8,496,710
Accumulated deficit	(24,755,793	)	(9,153,001	)
Accumulated other comprehensive income	428,220		288,990
Total shareholders’ equity (deficit)	4,139,453		(367,199	)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)	7,950,615		3,442,539

FAQ

What was MNDR's revenue growth in fiscal year 2024?

MNDR reported a 77% revenue increase to $14.0 million in fiscal year 2024, up from $7.9 million in fiscal year 2023.

How much was MNDR's net loss in FY 2024?

MNDR reported a net loss of $15.6 million ($0.56 per share) in fiscal year 2024, compared to a net loss of $3.2 million in fiscal year 2023.

What caused MNDR's increased operating expenses in FY 2024?

The main factors were $9.1 million in share-based compensation, $3.0 million increase in SG&A expenses related to IPO and operations, and $1.6 million increase in salaries and benefits.

How much did MNDR's telemedicine cases grow in FY 2024?

MNDR reported a 70% increase in the number of telemedicine cases compared to fiscal year 2023.